FDA approves Cyberonics' VNS (vagus nerve stimulation) anxiety trial:
This article was originally published in Clinica
Executive Summary
The US FDA has given Cyberonics the go-ahead to begin a pilot study to investigate the use of its implantable NCP vagus nerve stimulation (VNS) device as a treatment for three of five types of anxiety disorders - obsessive-compulsive disorder, panic disorder and adult onset post-traumatic stress disorder. The device, which was approved by the agency for the treatment of epilepsy in 1997, will be assessed in up to 30 patients at four sites, says the Houston, Texas company.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.